129 related articles for article (PubMed ID: 15087509)
1. An uncertain call to arms.
Fraser CM
Science; 2004 Apr; 304(5669):359. PubMed ID: 15087509
[No Abstract] [Full Text] [Related]
2. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
3. The development of antimicrobials and vaccines against bacterial bioterrorism agents--where are we?
Gilligan PH
Drug Discov Today; 2004 Mar; 9(5):205-6. PubMed ID: 14980537
[No Abstract] [Full Text] [Related]
4. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
5. Expanding Bioshield: a call for caution.
May T
Am J Public Health; 2007 Apr; 97 Suppl 1(Suppl 1):S23-5. PubMed ID: 17413075
[TBL] [Abstract][Full Text] [Related]
6. Policies in place throughout the world: action by the European Union.
Gouvras G
Int J Infect Dis; 2004 Oct; 8 Suppl 2():S21-30. PubMed ID: 15491872
[No Abstract] [Full Text] [Related]
7. Informed consent and public health: are they compatible when it comes to vaccines?
Parmet WE
J Health Care Law Policy; 2005; 8(1):71-110. PubMed ID: 16538802
[No Abstract] [Full Text] [Related]
8. Biodefense. Critics question proposed countermeasures agency.
Kaiser J
Science; 2005 Nov; 310(5749):755. PubMed ID: 16272086
[No Abstract] [Full Text] [Related]
9. Bioterrorism, public health, and international law.
Fidler DP
Chic J Int Law; 2002; 3(1):7-26. PubMed ID: 15709296
[No Abstract] [Full Text] [Related]
10. Bioterrorism: Agriculture shock.
Gewin V
Nature; 2003 Jan; 421(6919):106-8. PubMed ID: 12520273
[No Abstract] [Full Text] [Related]
11. Vaccines for the prevention of diseases caused by potential bioweapons.
Hassani M; Patel MC; Pirofski LA
Clin Immunol; 2004 Apr; 111(1):1-15. PubMed ID: 15093546
[TBL] [Abstract][Full Text] [Related]
12. World health and bioterrorism.
Vincent J
Clin Pharmacol Ther; 2009 Jun; 85(6):561-5. PubMed ID: 19451904
[No Abstract] [Full Text] [Related]
13. Cautious industry welcome for US flu vaccine plan.
Kling J
Nat Biotechnol; 2005 Dec; 23(12):1457-8. PubMed ID: 16333275
[No Abstract] [Full Text] [Related]
14. Cost/success projections for US biodefense countermeasure development.
Matheny J; Mair M; Smith B
Nat Biotechnol; 2008 Sep; 26(9):981-3. PubMed ID: 18779804
[No Abstract] [Full Text] [Related]
15. Staying ahead of the fourth horseman.
Rex JH
Nat Rev Microbiol; 2004 Sep; 2(9):684. PubMed ID: 15378807
[No Abstract] [Full Text] [Related]
16. An uncertain partnership.
Mulcahy RT
Science; 2003 Nov; 302(5647):949. PubMed ID: 14605331
[No Abstract] [Full Text] [Related]
17. Notes and comments "High and dry?" The Public Readiness and Emergency Preparedness Act and liability protection for pharmaceutical manufacturers.
Copper BK
J Health Law; 2007; 40(1):65-105. PubMed ID: 17549932
[TBL] [Abstract][Full Text] [Related]
18. Long wait almost over. Project Bioshield measure nears final approval.
Fong T
Mod Healthc; 2004 Jul; 34(29):18-9. PubMed ID: 15301143
[No Abstract] [Full Text] [Related]
19. Old legacies and new paradigms: confusing "research" and "treatment" and its consequences in responding to emergent health threats.
Javitt GH
J Health Care Law Policy; 2005; 8(1):38-70. PubMed ID: 16538801
[No Abstract] [Full Text] [Related]
20. A gift to pharma?
Nat Med; 2005 Jul; 11(7):693. PubMed ID: 16015340
[No Abstract] [Full Text] [Related]
[Next] [New Search]
